Table 1.

Patient characteristics

Total (N = 50)Responders (n = 25)Nonresponders (n = 25)
Age at TUR, y62.5 ± 8.961 ± 10.164 ± 7.3P > 0.05
Female sex, n (%)13 (26)6 (24)7 (28)
Ethnicity, n (%)
 Hispanic/Latino1 (2)0 (0)1 (4)
 Non-Hispanic/non-Latino48 (96)24 (96)24 (96)
 Unknown1 (2)1 (4)0 (0)
Race, n (%)
 Caucasian49 (98)25 (100)24 (96)
 African American1 (2)0 (0)1 (4)
Smoking status, n (%)
 Never13 (26)8 (32)5 (20)
 Former26 (52)13 (52)13 (52)
 Current11 (22)4 (16)7 (28)
Clinical staging, n (%)
 T237 (74)19 (76)18 (72)
 T310 (20)5 (20)5 (20)
 T43 (6)1 (4)2 (8)
 N040 (80)18 (72)22 (88)
 Node positive10 (20)7 (28)3 (12)
TUR histology, n (%)
 TCC32 (64)19 (76)13 (52)
 Mixed TCC18 (36)6 (24)12 (48)
Neoadjuvant chemotherapy regimen, n (%)
 GC31 (62)14 (56)17 (68)
 ddMVAC16 (32)9 (36)7 (28)
 GC-sunitinib2 (4)2 (8)0 (0)
 ddGC1 (2)0 (0)1 (4)
Median interval from chemotherapy to cystectomy (days ± SD)47 ± 29.946 ± 26.047 ± 33.8P > 0.05
Median length of follow-up (days ± SD)a351 ± 363.2372.5 ± 416.2329.5 ± 287.1P > 0.05
Patients with recurrence, n (%)13 (26)2 (8)11 (44)

NOTE: Clinical characteristics of the total patient cohort, as well as data stratified by responder or nonresponder status. Plus–minus values are medians ± SD.

Abbreviations: ddGC, dose-dense gemcitabine and cisplatin; ddMVAC, dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin; GC, gemcitabine and cisplatin; TUR, transuretheral resection.

  • aFor only patients alive at the time of this study. P < 0.05 is considered significant (Mann–Whitney test).